Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$36.06
-8.1%
$40.38
$26.20
$63.50
$1.66B1.47593,248 shs1.95 million shs
Galapagos NV stock logo
GLPG
Galapagos
$28.78
+1.0%
$27.87
$22.36
$31.23
N/A0.07250,426 shs87,611 shs
Indivior PLC stock logo
INDV
Indivior
$15.21
-2.2%
$12.87
$7.33
$15.88
$2.10B0.651.24 million shs891,806 shs
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$12.20
+1.3%
$11.02
$6.43
$29.74
$445.30MN/A164,505 shs63,821 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-17.48%-9.65%-4.25%+36.30%+3.21%
Galapagos NV stock logo
GLPG
Galapagos
-1.20%+1.79%+2.74%+21.13%+13.55%
Indivior PLC stock logo
INDV
Indivior
-3.33%+5.50%+10.52%+70.69%+2.98%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
0.00%+5.89%-4.90%+38.07%-49.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
2.8767 of 5 stars
3.52.00.00.02.44.20.0
Galapagos NV stock logo
GLPG
Galapagos
0.3141 of 5 stars
0.83.00.00.01.30.00.6
Indivior PLC stock logo
INDV
Indivior
2.0241 of 5 stars
1.63.00.00.03.11.71.9
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
1.2994 of 5 stars
3.50.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3.00
Buy$99.00174.54% Upside
Galapagos NV stock logo
GLPG
Galapagos
1.50
Reduce$25.33-11.98% Downside
Indivior PLC stock logo
INDV
Indivior
3.25
Buy$17.0011.77% Upside
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
3.00
Buy$28.00129.51% Upside

Current Analyst Ratings Breakdown

Latest RAPP, INDV, GLPG, and APGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$100.00 ➝ $115.00
7/2/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$116.00
6/30/2025
Indivior PLC stock logo
INDV
Indivior
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $22.00
4/8/2025
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Outperform$28.00
4/8/2025
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMkt Outperform
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$15.92 per shareN/A
Galapagos NV stock logo
GLPG
Galapagos
$298.31MN/A$0.72 per share39.71$47.57 per shareN/A
Indivior PLC stock logo
INDV
Indivior
$1.17B1.79$1.80 per share8.47($2.52) per share-6.04
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/A$8.35 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)
Galapagos NV stock logo
GLPG
Galapagos
$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)
Indivior PLC stock logo
INDV
Indivior
$2M-$0.31N/A8.89N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)

Latest RAPP, INDV, GLPG, and APGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
Indivior PLC stock logo
INDV
Indivior
$0.25N/AN/AN/AN/AN/A
7/23/2025Q2 2025
Galapagos NV stock logo
GLPG
Galapagos
-$0.34N/AN/AN/A$80.13 millionN/A
5/12/2025Q1 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.19-$0.95+$0.24-$0.95N/AN/A
5/8/2025Q1 2025
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$0.77-$0.68+$0.09-$0.68N/AN/A
4/24/2025Q1 2025
Indivior PLC stock logo
INDV
Indivior
$0.22$0.41+$0.19$0.38$240.13 million$266.00 million
4/23/2025Q1 2025
Galapagos NV stock logo
GLPG
Galapagos
-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
Galapagos NV stock logo
GLPG
Galapagos
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/A
15.82
15.82
Galapagos NV stock logo
GLPG
Galapagos
N/A
7.95
7.86
Indivior PLC stock logo
INDV
Indivior
N/A
0.88
0.72
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
31.01
31.01

Institutional Ownership

CompanyInstitutional Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
79.04%
Galapagos NV stock logo
GLPG
Galapagos
32.46%
Indivior PLC stock logo
INDV
Indivior
60.33%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
42.77%
Galapagos NV stock logo
GLPG
Galapagos
2.91%
Indivior PLC stock logo
INDV
Indivior
N/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
9146.05 million26.35 millionOptionable
Galapagos NV stock logo
GLPG
Galapagos
1,310N/AN/AOptionable
Indivior PLC stock logo
INDV
Indivior
1,051137.88 millionN/ANot Optionable
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A36.50 millionN/AN/A

Recent News About These Companies

Mise à disposition du rapport financier annuel 2024
Rapport Therapeutics initiated with an Outperform at Citizens JMP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$36.06 -3.18 (-8.10%)
As of 03:15 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Galapagos stock logo

Galapagos NASDAQ:GLPG

$28.78 +0.29 (+1.02%)
As of 03:15 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Indivior stock logo

Indivior NASDAQ:INDV

$15.21 -0.34 (-2.19%)
As of 03:10 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Rapport Therapeutics stock logo

Rapport Therapeutics NASDAQ:RAPP

$12.20 +0.16 (+1.33%)
As of 03:15 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.